Resources Blog Next-Gen Immuno-Oncology Conference 2024 – Boston: Highlights and Event Recap

Next-Gen Immuno-Oncology Conference 2024 – Boston: Highlights and Event Recap

Biointron 2024-06-24 Read time: 2 mins


The 7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference 2024 was held in Boston, MA on 20-21 June, 2024. The event brought together academics and scientists from research institutes and biopharmaceutical companies to discuss the latest updates, challenges, and future directions in immuno-oncology research. Topics discussed included: 

  • Updates in development of ADC’s and Bispecific Ab’s 

  • Immune Checkpoint Inhibitors and Combinations 

  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators) 

  • Biomarkers and Personalized Medicine in IO 

  • CAR-T Cell therapy, TCR Based-Cell Therapy 

  • Tumor microenvironment and Oncolytic Viruses 


→ Biointron’s Highlighted Points: 

1. Antibody Therapy Developments

  • Anchored immunotherapy within the tumor microenvironment results in prolonged drug retention and limited systemic toxicity; aluminium hydroxide as a stable anchoring scaffold.

  • Potential side effects of immunotherapies and best safety practices for managing them were discussed. (@Indaptus Therapeutics)  

  • B7-H7, a novel checkpoint axis for therapeutic targeting in cancer, suppresses T and NK cell activation through a novel immunosuppressive receptor.

  • Many of the recently approved or investigated approaches for melanoma immunotherapy require more answers to develop and enhance effective memory response against cancer cells.

2. Pre-clinical and Translational IO & Immune Checkpoint Blockades 

  • Polyploid giant cancer cells (PGCCs) are responsible for tumor progression, metastasis, chemoresistance and relapse. Key molecular pathways, therapeutic strategies, and computational methods were discussed.

  • Challenges and opportunities for the development of ADCs, bispecific immunomodulatory therapies, and combination; challenges to attaining the best therapeutic index.

  • Intrinsic differences in tumor biology due to post translation modifications and protein-protein interactions lead to racial disparity in breast cancer - understanding this can help in designing precision medicines.

  • Novel antibody-enabled targeted protein stabilization (TPS2) augments anti-tumor immune response by delivering Cbl-b inhibitor to immune cells while blocking checkpoint molecule, PD1.

Thank you for visiting us at our booth in NGIO 2024 to learn about our services! We had a great time connecting with you and understanding how we can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at or visit our website at

Subscribe to our Blog

Recent Blog

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.